1. Home
  2. MRKR vs ANY Comparison

MRKR vs ANY Comparison

Compare MRKR & ANY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • ANY
  • Stock Information
  • Founded
  • MRKR N/A
  • ANY N/A
  • Country
  • MRKR United States
  • ANY United States
  • Employees
  • MRKR N/A
  • ANY N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • ANY Finance: Consumer Services
  • Sector
  • MRKR Health Care
  • ANY Finance
  • Exchange
  • MRKR Nasdaq
  • ANY Nasdaq
  • Market Cap
  • MRKR 21.9M
  • ANY 25.2M
  • IPO Year
  • MRKR N/A
  • ANY N/A
  • Fundamental
  • Price
  • MRKR $1.57
  • ANY $0.67
  • Analyst Decision
  • MRKR Strong Buy
  • ANY Strong Buy
  • Analyst Count
  • MRKR 1
  • ANY 1
  • Target Price
  • MRKR $19.00
  • ANY $3.00
  • AVG Volume (30 Days)
  • MRKR 95.6K
  • ANY 366.5K
  • Earning Date
  • MRKR 03-25-2025
  • ANY 03-12-2025
  • Dividend Yield
  • MRKR N/A
  • ANY N/A
  • EPS Growth
  • MRKR N/A
  • ANY N/A
  • EPS
  • MRKR N/A
  • ANY N/A
  • Revenue
  • MRKR $5,395,849.00
  • ANY $21,657,000.00
  • Revenue This Year
  • MRKR $64.48
  • ANY N/A
  • Revenue Next Year
  • MRKR N/A
  • ANY N/A
  • P/E Ratio
  • MRKR N/A
  • ANY N/A
  • Revenue Growth
  • MRKR 79.04
  • ANY 38.44
  • 52 Week Low
  • MRKR $1.48
  • ANY $0.66
  • 52 Week High
  • MRKR $5.99
  • ANY $2.60
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 35.08
  • ANY 30.11
  • Support Level
  • MRKR $1.53
  • ANY $0.72
  • Resistance Level
  • MRKR $1.79
  • ANY $0.76
  • Average True Range (ATR)
  • MRKR 0.18
  • ANY 0.06
  • MACD
  • MRKR 0.03
  • ANY -0.00
  • Stochastic Oscillator
  • MRKR 14.52
  • ANY 2.49

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About ANY Sphere 3D Corp.

Sphere 3D Corp provides solutions for stand-alone storage and technologies that converge the traditional silos of compute, storage, and network into integrated hyper-converged or converged solution. Its Disk systems include HVE Converged and Hyper-converged Infrastructure. It generates the majority of its revenue from the services it offers. All of its revenue comes from the Americas. The Company has two operating segments: Digital Mining and Service and Product. The Digital Mining segment generates revenue from the digital currency, it earns through its bitcoin mining activities. The Service and Product segment generates revenue from long-term customer contracts for service contracts and extended service contract and the sale of products related to the Company's data storage product line.

Share on Social Networks: